GAA
PRME icon

Green Alpha Advisors’s Prime Medicine PRME Stock Holding History

Green Alpha Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$683K Sell
185,023
-6,148
-3% -$20.4K 0.46% 54
2026
Q1 		$665K Buy
191,171
+288
+0.2% +$1.1K 0.66% 45
2025
Q4 		$662K Buy
190,883
+530
+0.3% +$2.36K 0.61% 52
2025
Q3 		$1.05M Buy
190,353
+111,359
+141% +$452K 1.02% 32
2025
Q2 		$195K Sell
78,994
-4,473
-5% -$6.89K 0.19% 94
2025
Q1 		$166K Buy
83,467
+19,061
+30% +$48.6K 0.18% 97
2024
Q4 		$188K Buy
+64,406
New +$226K 0.15% 128
2024
Q3 		– Sell
-26,245
Closed -$135K – 143
2024
Q2 		$135K Sell
26,245
-7,493
-22% -$45.4K 0.11% 127
2024
Q1 		$236K Buy
33,738
+4,200
+14% +$31.9K 0.17% 128
2023
Q4 		$262K Sell
29,538
-8,277
-22% -$63.8K 0.19% 138
2023
Q3 		$361K Buy
37,815
+25,429
+205% +$330K 0.28% 115
2023
Q2 		$181K Buy
+12,386
New +$173K 0.12% 138

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Green Alpha Advisors's PRME Position: Q2 2026 in Review

Green Alpha Advisors reduced its Prime Medicine (PRME) stake by 3.2% in Q2 2026, selling an estimated $20.4K and leaving 185,023 shares worth $683K. The position accounts for 0.46% of the portfolio, ranked #54.

Green Alpha Advisors first reported a position in PRME in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.05M in Q3 2025. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Green Alpha Advisors held 185,023 shares of Prime Medicine worth $683K as of Q2 2026.
  • Green Alpha Advisors sold 6,148 Prime Medicine shares in Q2 2026, an estimated $20.4K.
  • Prime Medicine made up 0.46% of Green Alpha Advisors's portfolio in Q2 2026, its #54 holding.
  • Green Alpha Advisors first reported a position in Prime Medicine in Q2 2023 and has held it in 12 quarters since.
  • Green Alpha Advisors's Prime Medicine position peaked at $1.05M in Q3 2025.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.